Journal of Pain and Symptom Management
Volume 25, Issue 1 , Pages 74-91 , January 2003

Relationships Among Morphine Metabolism, Pain and Side Effects During Long-Term Treatment: An Update

  • Gertrud Andersen, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Gertrud Andersen, MD, Multidisciplinary Pain Center, Herlev University Hospital, 2730 Herlev, Denmark
    • Multidisciplinary Pain Center, Herlev University Hospital, Herlev, Denmark
    • ,
  • Lona Christrup, PhD

      Affiliations

    • The Royal Danish School of Pharmacy, Copenhagen, Denmark
    • ,
  • Per Sjøgren, MD

      Affiliations

    • Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark

,Accepted 8 March 2002.

References 

  1. Reisine T, Pasternak G. Opioid analgesics and antagonists. In:  Gilman AG,  Hardman JG,  Limbird LE editor. Goodman & Gilman's The pharmacological basis of therapeutics. 9th edition. New York: McGraw-Hill; 1996;p. 521–555
  2. Brunk SF, Delle M. Morphine metabolism in man. Clin Pharmacol Ther. 1974;16(1):51–57
  3. Lötsch J, Weiss M, Ahne G, et al.  Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers. Anesthesiology. 1999;90:1026–1038
  4. Tan T, Kuramoto M, Takahashi T, et al.  Characteristics of the gastrointestinal absorption of morphine in rats. Chem Pharm Bull (Tokyo). 1989;37(1):168–173
  5. Vater M, Smith G, Aherne GW, Aitkenhead AR. Pharmacokinetics and analgesic effect of slow-release oral morphine sulphate in volunteers. Br J Anaesth. 1984;56:821–827
  6. Säwe J, Dahlström B, Paalzow L, Rane A. Morphine kinetics in cancer patients. Clin Pharmacol Ther. 1981;30(5):629–635
  7. Säwe J, Kager L, Svensson J-O, Rane A. Oral morphine in cancer patients (in vivo kinetics and in vitro hepatic glucuronidation). Br J Clin Pharmacol. 1985;19:495–501
  8. Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration (demonstration of the importance of the active metabolite morphine-6-glucuronide). Clin Pharmacol Ther. 1990;47(1):12–19
  9. Yeh SY, Gorodetzky CW, Krebs HA. Isolation and identification of morphine 3- and 6-glucuronides, morphine 3,6-diglucuronide, morphine 3-ethereal sulfate, normorphine and normorphine 6-glucuronide as morphine metabolites in humans. J Pharm Sci. 1977;66(9):1288–1293
  10. Boerner U, Abbott S, Roe RL. The metabolism of morphine and heroin in man. Drug Metab Rev. 1975;4(1):39–73
  11. Mitchell JM, Paul BD, Welch P, Cone EJ. Forensic drug testing for opiates. II. Metabolism and excretion rate of morphine in humans after morphine administration. J Anal Toxicol. 1991;15(2):49–53
  12. Hasselström J, Säwe J. Morphine pharmacokinetics and metabolism in humans. Clin Pharmacokinet. 1993;24(4):344–354
  13. Yeh SY. Urinary excretion of morphine and its metabolites in morphine-dependent subjects. J Pharmacol Exp Ther. 1975;192(1):201–210
  14. Säwe J. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet. 1986;11:87–106
  15. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet. 1999;36(6):439–452
  16. Bodenham A, Quinn K, Park GR. Extrahepatic morphine metabolism in man during the anhepatic phase of orthotopic liver transplantation. Br J Anaesth. 1989;63:380–384
  17. Yue Q, Odar-Cederlöf I, Svensson J-O, Säwe J. Glucuronidation of morphine in human kidney microsomes. Pharmacol Toxicol. 1988;63:337–341
  18. Pacifici GM, Bencini C, Rane A. Presystemic glucuronidation of morphine in humans and rhesus monkeys (subcellular distibution of the UDP-glucuronyltransferase in the liver and intestine). Xenobiotica. 1986;16(2):123–128
  19. Mikus G, von Richter O, Hofmann U, et al. Glucuronidation of morphine in human liver and small intestine. Book of Abstracts, 9th World Congress on Pain. Vienna, 1999:335.
  20. Wahlström A, Winblad B, Bixo M, Rane A. Human brain metabolism of morphine and naloxone. Pain. 1988;35:121–127
  21. King CD, Rios GR, Assouline JA, Tephly TR. Expression of UDP-glucuronosyltransferases (UGTs) 2B7 and 1A6 in the human brain and identification of 5-hydroxytryptamine as a substrate. Arch Biochem Biophys. 1999;365(1):156–162
  22. Coughtrie MWH, Ask B, Rane A, et al.  The enantioselective glucuronidation of morphine in rats and humans. Evidence for the involvement of more than one UDP-glucuronosyltransferase isoenzyme. Biochem Pharmacol. 1989;38(19):3273–3280
  23. Wahlström A, Pacifici GM, Lindstrom B, et al.  Human liver morphine UDP-glucuronyl transferase enantioselectivity and inhibition by opioid congeners and oxazepam. Br J Pharmacol. 1988;94(3):864–870
  24. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Disp. 1997;25(1):1–4
  25. Crotty B, Watson KJR, Desmond PV, et al.  Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin Pharmacol. 1989;36:501–506
  26. Mazoit JX, Sandouk P, Scherrmann J-M, Roche A. Extrahepatic metabolism of morphine occurs in humans. Clin Pharmacol Ther. 1990;48(6):613–618
  27. Smith MT, Wright AWE, Williams BE, et al.  Cerebrospinal fluid and plasma concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide in patients before and after initiation of intracerebroventricular morphine for cancer pain management. Anesth Analg. 1999;88:109–116
  28. Sandouk P, Serrie A, Scherrmann JM, et al.  Presence of morphine metabolites in human cerebrospinal fluid after intracerebroventricular administration of morphine. Eur J Drug Metab Pharmacokinet. 1991;3:166–171
  29. Wolff T, Samuelsson H, Hedner T. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain. 1995;62:147–154
  30. Janicki PK, Erskine WAR, James MFM. The route of prolonged morphine administration affects the pattern of its metabolites in the urine of chronically treated patients. Eur J Clin Chem Clin Biochem. 1991;29:391–393
  31. Osborne R, Joel S, Grebenik K, et al.  The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther. 1993;54:158–167
  32. Patwardhan RV, Johnson RF, Hoyumpa A, et al.  Normal metabolism of morphine in cirrhosis. Gastroenterology. 1981;81:1006–1011
  33. Mazoit J-X, Sandouk P, Zetlaoui P, Scherrmann J-M. Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects. Anesth Analg. 1987;66:293–298
  34. Hasselström J, Eriksson S, Persson A, et al.  The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol. 1990;29:289–297
  35. Hoyumpa AM, Schenker S. Is glucuronidation truly preserved in patients with liver disease?. Hepatology. 1991;13(4):786–795
  36. Wolff J, Bigler D, Christensen CB, et al.  Influence of renal function on the elimination of morphine and morphine glucuronides. Eur J Clin Pharmacol. 1988;34:353–357
  37. Säwe J, Odar-Cederlöf I. Kinetics of morphine in patients with renal failure. Eur J Clin Pharmacol. 1987;32:377–382
  38. Pauli-Magnus C, Hofmann U, Mikus G, et al.  Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 1999;14:903–909
  39. Milne RW, Nation RL, Somogyi AA, et al.  The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br J Clin Pharmacol. 1992;34:53–59
  40. D'Honneur G, Gilton A, Sandouk P, et al.  Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. Anesthesiology. 1994;81:87–93
  41. Peterson GM, Randall CTC, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain (relationship to renal function and route of administration). Eur J Clin Pharmacol. 1990;38:121–124
  42. McQuay HJ, Carroll D, Faura CC, et al.  Oral morphine in cancer pain (influences on morphine and metabolite concentration). Clin Pharmacol Ther. 1990;48(3):236–244
  43. Tiseo PJ, Thaler HT, Lapin J, et al.  Morphine-6-glucuronide concentrations and opioid-related side effects (a survey in cancer patients). Pain. 1995;61:47–54
  44. Hanna MH, D'Costa F, Peat SJ, Fung C, Venkat N, Zilkha TR, et al. Morphine-6-glucuronide disposition in renal impairment. Br J Anaesth. 1993;70:511–514
  45. Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure (the role of morphine-6-glucuronide). Br Med J. 1986;292:1548–1549
  46. Bodd E, Jacobsen D, Lund E, et al.  Morphine-6-glucuronide might mediate the prolonged opioid effect of morphine in acute renal failure. Human Exp Toxicol. 1990;9:317–321
  47. Hasselström J, Berg U, Löfgren A, Säwe J. Long lasting respiratory depression induced by morphine-6-glucuronide?. Br J Clin Pharmacol. 1989;27:515–518
  48. Sjøgren P, Dragsted L, Christensen CB. Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol Scand. 1993;37:780–782
  49. Zhou HH, Sheller JR, Nu H, et al.  Ethnic differences in response to morphine. Clin Pharmacol Ther. 1993;54:507–513
  50. Aasmundstad TA, Størset P. Influence of ranitidine on the morphine-3-glucuronide to morphine-6-glucuronide ratio after oral administration of morphine in humans. Hum Exp Toxicol. 1998;17:347–352
  51. Wahlström A, Lenhammar L, Ask B, Rane A. Tricyclic antidepressants inhibit opioid receptor binding in human brain and hepatic morphine glucuronidation. Pharmacol Toxicol. 1994;75:23–27
  52. Ventafridda V, Ripamonti C, De Conno F, et al.  Antidepressants increase bioavailability of morphine in cancer patients. Lancet. 1987;1(8543):1204
  53. Choonara IA, McKay P, Hain R, Rane A. Morphine metabolism in children. Br J Clin Pharmacol. 1989;28:599–604
  54. Lynn A, Nespeca MK, Bratton SL, et al.  Clearance of morphine in postoperative infants during intravenous infusion (the influence of age and surgery). Anesth Analg. 1998;86:958–963
  55. McRorie TI, Lynn AM, Nespeca MK, et al.  The maturation of morphine clearance and metabolism. Am J Dis Child. 1992;146(8):972–976
  56. Kaiko RF. Age and morphine analgesia in cancer patients with postoperative pain. Clin Pharmacol Ther. 1980;28(6):823–826
  57. Moore AK, Vilderman S, Lubenskyi W, McCans J, Fox GS. Differences in epidural morphine requirements between elderly and young patients after abdominal surgery. Anesth Analg. 1990;70:316–320
  58. Owen JA, Sitar DS, Berger L, et al.  Age-related morphine kinetics. Clin Pharmacol Ther. 1983;34(3):364–368
  59. Sear JW, Hand CW, Moore RA. Studies on morphine disposition (plasma concentrations of morphine and its metabolites in anesthetized middle-aged and elderly surgical patients). J Clin Anesth. 1989;1(3):164–169
  60. Gourlay GK, Plummer JL, Cherry DA, Purser T. The reproducibility of bioavailability of oral morphine from solution under fed and fasted conditions. J Pain Symptom Manage. 1991;6(7):431–436
  61. Säwe J, Svensson JO, Rane A. Morphine metabolism in cancer patients on increasing oral doses—no evidence for autoinduction or dose-dependence. Br J Clin Pharmacol. 1983;16:85–93
  62. Vermeire A, Remon JP, Rosseel MT, et al.  Variability of morphine disposition during long-term subcutaneous infusion in terminally ill cancer patients. Eur J Clin Pharmacol. 1998;53:325–330
  63. Carrupt PA, Testa B, Bechalany A, et al.  Morphine-6-glucuronide and morphine-3-glucuronide as molecular chameleons with unexpected lipophilicity. J Med Chem. 1991;34(4):1272–1275
  64. Lötsch J, Stockmann A, Kobal G, et al.  Pharmacokinetics of morphine and its glucuronides after intravenous infusion of morphine and morphine-6-glucuronide in healthy volunteers. Clin Pharmacol Ther. 1996;60:316–325
  65. Hanna MH, Peat SJ, Knibb AA, Fung C. Disposition of morphine-6-glucuronide and morphine in healthy volunteers. Br J Anaesth. 1991;66:103–107
  66. Hoskin PJ, Hanks GW, Aherne GW, et al.  The bioavailability and pharmakokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol. 1989;27:499–505
  67. Gourlay GK, Plummer JL, Cherry DA, Onley MM. A comparison of Kapanol (a new sustained-release morphine formulation), MST Continus and morphine solution in cancer patients (pharmacokinetic aspects of morphine and morphine metabolites). In:  Gebhart GF,  Hammond DL,  Jensen TS editor. Procedings of the 7th World Congress on Pain, Progress in Pain Research and Management, vol 2. Seattle: IASP; 1994;p. 631–643
  68. Poulain P, Hoskin PJ, Hanks GW, et al.  Relative bioavailability of controlled release morphine tablets (MST Continus) in cancer patients. Br J Anaesth. 1988;61:569–574
  69. Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure (the role of morphine-6-glucuronide). Br Med J. 1986;292:1548–1549
  70. Christrup LL, Sjogren P, Jensen N-H, et al.  Steady-state kinetics and dynamics of morphine in cancer patients. Is sedation related to the absorption rate of morphine?. J Pain Symptom Manage. 1999;18(3):164–173
  71. Stain F, Barjavel MJ, Sandouk P, et al.  Analgesic response and plasma and brain extracellular fluid pharmacokinetics of morphine and morphine-6-beta-D-glucuronide in the rat. J Pharmacol Exp Ther. 1995;274(2):852–857
  72. Aasmundstad TA, Mørland J, Paulsen RE. Distribution of morphine 6-glucuronide and morphine across the blood-brain barrier in awake, freely moving rats investigated by in vivo microdialysis sampling. J Pharmacol Exp Ther. 1995;275(1):435–441
  73. Barjavel M, Sandouk P, Plotkine M, Scherrmann JM. Morphine and morphine metabolite kinetics in the rat brain as assessed by transcortical microdialysis. Life Sci. 1994;55(16):1301–1308
  74. Murphey LJ, Olsen GD. Diffusion of morphine-6-beta-D-glucuronide into the neonatal guinea pig brain during drug-induced respiratory depression. J Pharmacol Exp Ther. 1994;271:118–124
  75. Wu D, Kang Y-S, Bickel U, Pardridge WM. Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Drug Metab Dispos. 1997;25(6):768–771
  76. Bickel U, Schumacher OP, Kang Y-S, Voigt K. Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. J Pharmacol Exp Ther. 1996;278(1):107–113
  77. Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology. 2000;92:1392–1399
  78. Huwyler J, Drewe J, Klusemann C, Fricker G. Evidence for P-glycoprotein-modulated penetration of morphine-6-glucuronide into brain capillary endothelium. Br J Pharmacol. 1996;118:1879–1885
  79. Callaghan R, Riordan JR. Synthetic and natural opiates interact with P-glycoprotein in multidrug-resistant cells. J Biol Chem. 1993;268:16059–16064
  80. Goucke CR, Hackett LP, Ilett KF. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain. Pain. 1994;56:145–149
  81. Van Dongen RTM, Crul BJP, Koopman-Kimenai PM, Vree TB. Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine. Br J Clin Pharmacol. 1994;38(3):271–273
  82. Portenoy RK, Khan E, Layman M, et al.  Chronic morphine therapy for cancer pain (plasma and cerebrospinal fluid morphine and morphine- 6-glucuronide concentrations). Neurology. 1991;41:1457–1461
  83. Wolff T, Samuelsson H, Hedner T. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients. Pain. 1996;68:209–216
  84. Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE. Morphine-6-glucuronide, a potent mu agonist. Life Sci. 1987;41:2845–2849
  85. Barlett SE, Dodd PR, Smith MT. Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites. Pharmacol Toxicol. 1994;75:73–81
  86. Hucks D, Thompson PI, McLoughlin L, et al.  Explanation at the opioid receptor level for differing toxicity of morphine and morphine-6-glucuronide. Br J Cancer. 1992;65:122–126
  87. Frances B, Gout R, Monsarrat B, et al.  Further evidence that morphine-6β-glucuronide is a more potent opioid agonist than morphine. J Pharmacol Exp Ther. 1992;262(1):25–31
  88. Paul D, Standifer KM, Inturrisi CE, Pasternak GW. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther. 1989;251(2):477–483
  89. Stain-Texier F, Boschi G, Sandouk P, Scherrmann JM. Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability. Br J Pharmacol. 1999;128(4):917–924
  90. Motamed C, Mazoit X, Ghanouchi K, et al.  Preemptive intravenous morphine-6-glucuronide is ineffective for postoperative pain relief. Anesthesiology. 2000;92:355–360
  91. Lötsch J, Kobal G, Stockmann A, et al.  Lack of analgesic activity of morphine-6-glucuronide after short-term intravenous administration in healthy volunteers. Anesthesiology. 1997;87:1348–1358
  92. Hanna MH, Peat SJ, Woodham M, Knibb A, Fung C. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide (comparison with morphine). Br J Anaesth. 1990;64:547–550
  93. Grace D, Fee JPH. A comparison of intrathecal morphine-6-glucuronide and intrathecal morphine sulfate as analgesics for total hip replacement. Anesth Analg. 1996;83:1055–1059
  94. Thompson PI, Joel SP, John L, et al.  Respiratory depression following morphine and morphine-6-glucuronide in normal subjects. Br J Clin Pharmacol. 1995;40:145–152
  95. Osborne R, Thompson P, Joel S, et al.  The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol. 1992;34:130–138
  96. Peat S, Hanna M, Durcan T, Fung M. Morphine-6-glucuronide in postoperative pain. Book of Abstracts, 9th World Congress on Pain, Vienna, Austria, 1999:335.
  97. Faura CC, Moore A, Horga JF, et al.  Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain. J Pain Symptom Manage. 1996;11(2):95–102
  98. Portenoy RK, Thaler HT; Inturrisi CE , et al.  The metabolite morphine-6-glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function. Clin Pharmacol Ther. 1992;51(4):422–431
  99. Klepstad P, Kaasa S, Borchgrevink PC. Start of oral morphine to cancer patients (effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine). Eur J Clin Pharmacol. 2000;55(10):713–719
  100. Dennis GC, Soni D, Dehkordi O, et al.  Analgesic responses to intrathecal morphine in relation to CSF concentrations of morphine-3,β-glucuronide and morphine-6,β-glucuronide. Life Sci. 1999;64:1725–1731
  101. Somogyi AA, Nation RL, Olweny C, et al.  Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine. Clin Pharmacokinet. 1993;24(5):413–420
  102. Samuelsson H, Hedner T, Venn R, Michalkiewicz A. CSF and plasma concentrations of morphine and morphine glucuronides in cancer patients receiving epidural morphine. Pain. 1993;52:179–185
  103. Hoffman M, Xu JC, Smith C, et al.  A pharmacodynamic study of morphine and its glucuronide metabolites after single morphine dosing in cancer patients with pain. Cancer Invest. 1997;15(6):542–547
  104. Gong Q-L, Hedner T, Hedner J, et al.  Antinociceptive and ventilatory effects of the morphine metabolites (morphine-6-glucuronide and morphine-3-glucuronide). Eur J Pharmacol. 1991;193:47–56
  105. Pelligrino DA, Riegler FX, Albrecht RF. Ventilatory effects of fourth cerebroventricular infusions of morphine-6- or morphine-3-glucuronide in the awake dog. Anesthesiology. 1989;71(6):936–940
  106. Ling GSF, Spiegel K, Lockhart SH, Pasternak GW. Separation of opioid analgesia from respiratory depression (evidence for different receptor mechanisms). J Pharmacol Exp Ther. 1985;232(1):149–155
  107. Thompson PI, Bingham S, Andrews PL, et al.  Morphine-6-glucuronide (a metabolite of morphine with greater emetic potency than morphine in the ferret). Br J Pharmacol. 1992;106(1):3–8
  108. Hagen NA, Foley KM, Cerbone DJ, et al.  Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage. 1991;6(3):125–128
  109. Ashby M, Fleming B, Wood M, Somogyi A. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice patients. J Pain Symptom Manage. 1997;14(3):157–167
  110. Westerling D, Persson C, Höglund P. Plasma concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide after intravenous and oral administration to healthy volunteers (relationship to nonanalgesic actions). Ther Drug Monit. 1995;17:287–301
  111. Andersen G, Christrup L, Sjøgren P, et al.  Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained release morphine. Palliat Med. 2002;16:107–114
  112. Faura CC, Olaso MJ, Cabanes GC, Horga JF. Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved?. Pain. 1996;65:25–30
  113. Gong Q-L, Hedner J, Björkman R, Hedner T. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain. 1992;48:249–255
  114. Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide—a potent antagonist of morphine analgesia. Life Sci. 1990;47(6):579–585
  115. Smith GD, Smith MT. Morphine-3-glucuronide (evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat). Pain. 1995;62:51–60
  116. Bian J-T, Bhargava HN. Effects of morphine-3-glucuronide on the antinociceptive activity of peptide and nonpeptide opioid receptor agonists in mice. Peptides. 1996;17(8):1415–1419
  117. Hewett K, Dickenson AH, McQuay HJ. Lack of effect of morphine-3-glucuronide on the spinal antinociceptive actions of morphine in the rat (an electrophysiological study). Pain. 1993;53:59–63
  118. Quellet DM-C, Pollack GM. Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception. Biochem Pharmacol. 1997;53(10):1451–1457
  119. Lipkowski AW, Carr DB, Langlade A, et al.  Morphine-3-glucuronide (silent regulator of morphine actions). Life Sci. 1994;55(2):149–154
  120. Bowsher D. Paradoxical pain. When metabolites of morphine are in the wrong ratio. Br Med J. 1993;306:473–474
  121. Labella FS, Pinsky C, Havlicek V. Morphine derivatives with diminished opiate receptor potency show enhanced central excitatory activity. Brain Res. 1979;174:263–271
  122. Barlett SE, Cramond T, Smith MT. The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. Life Sci. 1994;54(10):687–694
  123. Snead OC. Opiate-induced seizures (a study of mu and delta specific mechanisms). Exp Neurol. 1986;93(2):348–358
  124. Woolf CJ. Intrathecal high dose morphine produces hyperalgesia in the rat. Brain Res. 1981;209(2):491–495
  125. Yaksh TL, Harty GJ, Onofrio BM. High doses of spinal morphine produce a nonopiate receptor-mediated hyperesthesia (clinical and theoretic implications). Anesthesiology. 1986;64(5):590–597
  126. Yaksh TL, Harty GJ. Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. J Pharmacol Exp Ther. 1988;244(2):501–507
  127. Shohami E, Evron S, Weinstock M, Soffer D, Carmon A. A new animal model for action myoclonus. Adv Neurol. 1986;43:545–552
  128. Lufty K, Woodward RM, Keana JFW, Weber E. Inhibition of clonic seizure-like excitatory effects induced by intrathecal morphine using two NMDA receptor antagonists (MK-801 and ACEA-1011). Eur J Pharmacol. 1994;252(3):261–266
  129. Morley JS, Miles JB, Wells JC, Bowsher D. Paradoxical pain. Lancet. 1992;340:1045
  130. Sjøgren P, Thünedborg LP, Christrup L, Hansen SH, Franks J. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration?. Acta Anaesthesiol Scand. 1998;42:1070–1075
  131. Hagen N, Swanson R. Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration (treatment strategies). J Pain Symptom Manage. 1997;14:51–58
  132. Rozan JP, Kahn CH, Warfield CA. Epidural and intravenous opioid-induced neuroexcitation. Anesthesiology. 1995;83:860–863
  133. Kronenberg MF, Laimer I, Rifici C, et al.  Epileptic seizure associated with intracerebroventricular and intrathecal morphine bolus. Pain. 1998;75:383–387
  134. Sjøgren P, Jensen N-H, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain. 1994;59:313–316

PII: S0885-3924(02)00531-6

Journal of Pain and Symptom Management
Volume 25, Issue 1 , Pages 74-91 , January 2003

Article Tools

* Image Usage & Resolution